These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8704279)

  • 1. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin.
    Yang X; Pagé M
    Oncol Res; 1995; 7(12):619-24. PubMed ID: 8704279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
    Yan XD; Li M; Yuan Y; Mao N; Pan LY
    Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of multidrug resistance in a canine lymphoma cell line.
    Uozurmi K; Nakaichi M; Yamamoto Y; Une S; Taura Y
    Res Vet Sci; 2005 Jun; 78(3):217-24. PubMed ID: 15766940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
    Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance.
    Leveille-Webster CR; Arias IA
    Clin Cancer Res; 1996 Apr; 2(4):695-706. PubMed ID: 9816220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.
    Choi CH; Kang G; Min YD
    Planta Med; 2003 Mar; 69(3):235-40. PubMed ID: 12677527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Zhang T; Guan M; Jin HY; Lu Y
    Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer].
    Liang Z; Bian D
    Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):75-8. PubMed ID: 8758797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
    Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
    Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-resistance to antitumor diarylsulfonylureas and collateral sensitivity to mitochondrial toxins in a human cell line selected for resistance to the antitumor agent N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea.
    Sosinski J; Thakar JH; Germain GS; Dias P; Harwood FC; Kuttesch JF; Houghton PJ
    Mol Pharmacol; 1994 May; 45(5):962-70. PubMed ID: 7910660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
    Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS
    Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance.
    Minderman H; Vanhoefer U; Toth K; Minderman MD; Rustum YM
    Cancer; 1996 Dec; 78(11):2427-36. PubMed ID: 8941015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha.
    Licht T; Lübbert M; Martens C; Bross KJ; Fiebig HH; Mertelsmann R; Herrmann F
    Cytokines Mol Ther; 1995 Jun; 1(2):123-32. PubMed ID: 9384669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells.
    Shen X; Chen G; Zhu G; Fong WF
    Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance.
    Smith CD; Carmeli S; Moore RE; Patterson GM
    Cancer Res; 1993 Mar; 53(6):1343-7. PubMed ID: 8095179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
    Chen G; Teicher BA; Frei E
    Anticancer Res; 1996; 16(6B):3499-505. PubMed ID: 9042212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of mdr1 antisense oligodeoxynucleotides on reversal of multidrug resistance in ovarian carcinoma cell line SKOV3].
    Tong Y; Pan L; Zhou S
    Zhonghua Fu Chan Ke Za Zhi; 2000 Nov; 35(11):677-9. PubMed ID: 11218898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.